The fervor over American companies merging with overseas rivals to lower their tax rates has drawn the ire of the Obama Administration, possibly imperiling the so-called inversion deals that have become increasingly popular in biopharma.

…read more

Source: ‘Economic patriotism’ could dampen biopharma’s M&A boom